# A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

> **NCT06305663** · NA · RECRUITING · sponsor: **Bausch & Lomb Incorporated** · enrollment: 418 (estimated)

## Conditions studied

- Myopia

## Interventions

- **DEVICE:** Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)
- **DEVICE:** CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens

## Key facts

- **NCT ID:** NCT06305663
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-29
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 418 (ESTIMATED)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06305663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06305663, "A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06305663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*